Futura Medical has formed a new US commercial partnership with Market Performance Group (MPG) to manage sales, marketing, and distribution of its Eroxon product, shifting from a traditional licensing model to a more active commercial strategy. The company also announced encouraging clinical trial results for its women's sexual health product candidate, WSD4000, showing significant improvements in sexual function and positive user feedback. Plans are underway to start a Phase 3 pivotal trial for WSD4000, aiming for regulatory approval and a potential launch in early 2028 in the US and Europe. These developments highlight Futura Medical's strategic growth and product potential in consumer healthcare.
Bitcoin and Ethereum posted small gains while major altcoins showed mixed results, reflecting cautious investor sentiment and a preference for Bitcoin's relative stability. Bitcoin dominance increased slightly to 58.51%, signaling a defensive market ...
CoreWeave secured $3.1 billion in financing backed by high-performance computing (HPC), attracting about $19 billion in demand, highlighting strong institutional trust in AI infrastructure investments. Despite a 14% stock drop triggered by Meta Compu...
Circle, issuer of USD Coin (USDC), received approval to operate as a federally regulated trust bank in the U.S., marking a key step in integrating stablecoins into traditional finance. This approval supports Circle's expansion of institutional custod...
Metaplanet is developing a digital credit system that leverages Bitcoin, JPYC stablecoin, and security tokens. This initiative aims to create new financial products that combine cryptocurrency and traditional credit mechanisms, potentially increasing...
XRP rose 1.27% to $1.10 as the CLARITY Act advanced through the Senate Banking Committee, potentially clarifying crypto regulations. Analysts highlight $0.85–$1.20 as a key accumulation range, with targets up to $15 in the long term. XRP ETF inflows ...
